Health and Fitness Health and Fitness
Thu, June 3, 2010

Implant Sciences Completes Air Cargo Screening Trial at Boston's Logan International Airport


Published on 2010-06-03 04:11:25 - Market Wire
  Print publication without navigation


WILMINGTON, MA--(Marketwire - June 3, 2010) - Implant Sciences Corporation (PINKSHEETS: [ IMSC ]), a high technology supplier of systems and sensors for homeland security and defense markets, today announced the completion of its air cargo screening trial in conjunction with East Coast Airport Services (ECAS). The trial is part of a larger air cargo pilot program being conducted to provide insight to the Company and its customers as they develop effective and efficient operational protocols to satisfy the requirements of US Public Law 110-53 "Implementing Recommendations of the 9/11 Commission Act of 2007."

"Implant Science's air cargo pilot program, combined with ongoing verification and validation activities and the recent Department of Homeland Security SAFETY Act designation of the Quantum Sniffer as a Qualified Anti-Terrorism Technology, will help to ensure the Company's success in Air Cargo Screening markets," stated Todd Silvestri, VP of Technology for Implant Sciences.

Glenn D. Bolduc, CEO, added, "Implant Sciences is excited to have the opportunity to evaluate our technologies in a world class air cargo screening facility with the challenging environmental conditions that are presented there. We would like to thank ECAS for this opportunity which will ultimately help the Company achieve its goal of delivering superior technologies exceeding customer expectations."

The trial was conducted in ECAS's air cargo screening facilities at Boston Logan International Airport. The agreement to conduct the trial was facilitated by the Massachusetts Port Authority (Massport) which owns and operates Logan Airport.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. For further details on the Company and its products, please visit the Company's website at [ www.implantsciences.com ]

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the U.S. government or by other law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contributing Sources